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Background: Diets rich in dairy and/or calcium (Ca) have been associated with reductions in adiposity and
inflammation, but the mechanisms underlying this remain to be fully elucidated. Oxylipins and endocannabinoids
are bioactive lipids, which influence energy homeostasis, adipose function, insulin signaling, and inflammation. Our
objective was to determine if these metabolites associate with metabolic and inflammatory phenotypes stemming
from dietary Ca and dairy in diet induced obese mice.
Methods: In one study, C57BL6/J mice were fed high fat diets (45% energy) with varying dietary matrices for
12 weeks: soy protein and Ca adequate (0.5%; CONTROL), soy protein and high Ca (1.5%; HighCa), or nonfat-dry-milk
based high Ca (NFDM). In a second study, mice were pre-fattened for 12 weeks on the CONTROL high fat diet, and
then fed one of three high fat diets for an additional 8 weeks: CONTROL, HighCa, or NFDM. In both studies, adiposity
and associated metabolic and inflammatory outcomes were measured and a targeted lipidomics analysis was
performed on plasma collected during the post-absorptive condition.
Results: As reported previously, mice fed NFDM had less body fat and reduced mRNA markers of adipose
inflammation (p < 0.05) than CONTROL mice despite greater cumulative energy intake. Moreover, NFDM fed mice
lipid mediator profiles were distinct from CONTROL and HighCa mice. NFDM fed mice showed elevated plasma
monoacylglycerols (6 – 46% increase from CONTROL), including 2-arachidonoylglycerol (2-AG), and reduced fatty
acid diols (8-75% decrease from CONTROL).
Conclusions: Differences in specific plasma lipid mediator profiles reflect the metabolic and inflammatory
phenotypes seen in NFDM feeding.Background
Obesity has been characterized as a state of chronic in-
flammation, displaying increased macrophage and adipo-
cyte release of interleukins and inflammatory cytokines as
well as macrophage accumulation in adipose tissue [1,2].
The presence of this low-grade systemic inflammation
contributes to the pathogenesis of metabolic diseases (i.e.
insulin resistance, diabetes, cardiovascular disease) [3,4].
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interest in identifying foods and micronutrients that
can dampen the inflammatory profile independent of
weight. For instance, there is strong epidemiological evi-
dence to suggest a beneficial effect of dairy consumption
on adiposity and inflammation [6,7], but randomized trials
in humans are inconclusive [8-10]. Differences in specific
dietary components or dairy foods in these studies may be
responsible for the disparity of results. Furthermore, it can
be difficult to dissociate inflammatory outcomes from
changes in adiposity, since the latter directly correlates
with white adipose tissue (WAT) macrophage infiltration
and inflammatory markers over a wide range, at least in
mice [11]. Therefore, it is important to identify whichtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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exert anti-inflammatory and anti-obesity effects.
One proposed mechanism by which dairy can improve
inflammatory status is through dairy-derived calcium’s
ability to suppress circulating levels of 1,25-dihydroxyviat-
min D3 (calcitriol). In vivo evidence has shown increased
dietary calcium, both with and without dairy, diminished
inflammation and oxidative stress in genetically-modified
obese animals, with the interpretive caveat that adiposity
was also reduced under these conditions [12]. Increased
dietary calcium dampens circulating calcitriol, and calci-
triol has been shown to activate pro-inflammatory path-
ways by inducing reactive oxygen species generation and
cytokine release in adipocytes and macrophages [13,14].
However, anti-inflammatory actions of calcitriol have also
been reported in humans [15], and serum calcitriol has
been reported to be significantly lower in obese verses
non-obese human subjects [16]. In diet-induced obese
(DIO) mice fed high calcium or high-calcium plus dairy,
circulating calcitriol did not correlate with alterations in
systemic or WAT inflammation [17,18]. Thus, changes in
calcitriol due to dietary calcium cannot fully explain the
apparent anti-inflammatory effects of dairy.
Non-calcium components in dairy foods could also
play a role in obesity-associated inflammation and regu-
lation of metabolism. Dairy bioactives such as lactalbumin,
angiotensin-converting enzyme inhibitor and branched-
chain amino acids may modify metabolic and other
physiological functions [19-23]. Additionally, evidence in-
dicates that dairy proteins may have beneficial effects on
appetite in humans [24], glucose metabolism and muscle
protein synthesis [25], as well as improve fasting lipid and
insulin levels [26,27]. In animal models of obesity, inclu-
sion of dairy or dairy-based proteins in the diet reduces
weight gain and adiposity, even in the absence of lower
energy intake. In some studies in DIO mice fed a high fat
diet containing a dairy matrix (e.g., a calcium rich, non-fat
dry milk (NFDM) protein and carbohydrate-based diet),
energy intake was modestly increased, resulting in lower
feed efficiency [17,18]. The etiology of these effects on
food intake and energy balance remains to be ascertained.
Systemic energy balance is delicately regulated by mul-
tiple interactive systems, including a suite of endocanna-
binoids (eCBs) and oxylipins, low abundance signaling
lipids present in the open circulation and tissues. To
date, no attention has been given to the impact of a
dairy-based diet on these lipid mediators, despite their
roles in inflammation, food intake behaviors, thermogen-
esis, and a variety of other processes [28,29]. Oxylipins,
oxygenated products of fatty acid metabolism that in-
clude the arachidonic acid-derived eicosanoids, have
numerous bioactive properties including both pro- and
anti-inflammatory effects [30], constrictive and dilatory
vascular effects [31], and effects on insulin signaling[29,32]. The eCBs are lipid mediators that elicit effects on
energy homeostasis and immune function through inter-
actions with the cannabinoid type 1 and type 2 (CB1 and
CB2) receptors and transient receptor potential cation
channel 1 (TRPV1). eCBs may also bind and activate per-
oxisome proliferator-activated receptor γ (PPARγ), a tran-
scription factor that regulates genes to promote lipid
storage (and immunomodulation) [33]. The archetypical
eCBs are the arachidonate-derived 2-archidonoylglycerol
(2-AG) and N-arachidonoyl-ethanolamine (AEA). In addition
to neuromodulatory effects on appetite, eCB signaling
has been implicated in the pathogenesis of obesity by
actions that promote lipogenesis in adipose and liver,
and may also regulate insulin sensitivity [34-36].
Besides the effects of dietary long chain PUFAs on cir-
culating oxylipins and eCBs concentrations [37,38], the
impact of other nutrients on these systems is not known.
Given the putative role of dairy and calcium in adiposity
and inflammation, we hypothesized that these nutrients
would impact signaling lipid profiles, and we tested this
under conditions of both developing and pre-existing
obesity. Using targeted quantitative metabolic profiling
we performed a secondary analysis of archived plasma
from a previous study investigating the effects of dairy and
calcium on inflammatory phenotypes in a DIO mouse
model [17,18]. As previously reported, animals fed a high
fat diet rich in calcium in a NFDM-based matrix showed
decreased adiposity, markedly reduced steatosis, and lower
adipose inflammation in comparison to a high-calcium,
soy protein-based high fat diet [17,18]. In the current
study, signaling lipid profiling, gene expression, and gross
morphometric parameters were used to describe pheno-
types in high fat fed mice that best discriminated NFDM
protein and carbohydrate-fed mice from animals fed soy
protein/sucrose carbohydrate-based diets. We contend
that the identified shifts in oxylipin and endocannabinoid
tone may be associated with biochemical and physiological
processes that drive the markedly different energy balance




All animal protocols were approved by the University of
California at Davis Institutional Animal Care and Use
Committee according to Animal Welfare Act guidelines.
COHORT 1: developing obesity model
Details for Cohort 1 regarding housing conditions, diets,
tissue/blood collection and other experimental variables
have been previously published [17]. In brief, 5 week old
C57BL/6 J weight-matched male mice were randomly
assigned to one of three obesogenic diets containing
45% energy as fat (lard) for 12 weeks. This diet and
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obesity along with increased WAT inflammation and
insulin resistance in this model [11]. Treatment groups
were: 1) soy protein- and sucrose carbohydrate based
control (0.5% calcium, CONTROL), 2) soy and sucrose-
based high-calcium (1.5% calcium, HighCa), or 3) high-
calcium (1.5%) in the context of non-fat dry milk protein
and carbohydrates (NFDM). Mice were given free access
to food and water with body weight and food intake (plus
spillage) measurements made every 2–3 d. At week 12,
mice were briefly food deprived (ca. 4–6 hr into the light
cycle) in the morning prior to being deeply anesthetized
via isoflurane inhalation (3% in O2). After exposing the
diaphragm, blood was collected by cardiac puncture using
EDTA-treated syringes. Mice did not survive this proced-
ure. Blood plasma was subsequently collected by centrifu-
gation at 10,000 × g for 2 minutes and snap-frozen in
liquid nitrogen. Retroperitoneal white adipose tissue (RP-
WAT), liver, and nodose ganglia were excised and snap-
frozen in liquid nitrogen. All tissues were stored at −80°C.
A subsample of animals (n = 10/treatment group) was ran-
domly selected for plasma and tissue analysis.
COHORT 2: pre-existing obesity model
Details for Cohort 2 regarding housing conditions, diets,
and other variables have been previously published [18].
In brief, 5 week old C57BL/6 J male mice were fed the
CONTROL diet for 12 weeks. After the 12 week, pre-
fattening period, weight-matched DIO mice were ran-
domly assigned to one of three macronutrient-matched
high fat diets for an additional 8 weeks: 1) CONTROL,
2) HighCa, or 3) NFDM. At week 8 of intervention, mice
were briefly food deprived prior to tissue and blood collec-
tion (described above). A subsample of animals (n = 10/
treatment group) was randomly selected for plasma and
tissue analysis.
Plasma lipid mediator profiling
Calibrants and isotopically labeled surrogates were pur-
chased from either Cayman Chemical (Ann Arbor, MI) or
Larodan Fine Chemicals (Malmo, Sweden). Calibration
solutions were prepared in 50/50 acetonitrile:methanol
(v/v), ampuoled under dry nitrogen, and stored at -20°C
until use. Analyte retention times, surrogates-associations,
and tandem mass spectrometry parameters are provided
in Additional file 1: Table S5. Oxylipins and eCBs were
isolated by solid phase extraction and quantified by
LC-MS/MS using modifications of published protocols
[39,40]. Briefly, plasma aliquots (100 μL; n = 10/group)
were first introduced to 60 mg Oasis HLB (Waters
Corporation, Milford, MA) SPE cartridges reservoirs,
enriched with deuterated oxylipin and eCB surrogates
and antioxidants (BHT/EDTA), and diluted with 2 mL
of 5% methanol/0.1% acetic acid. Samples were loadedby gravity, washed with 20% methanol/0.1% acetic acid and
air dried. Loaded cartridges were then wetted with metha-
nol and eluted with ethyl acetate into 6 μL glycerol, and
the solvent was evaporated under vacuum. The resulting
glycerol plug was stored at -80°C until reconstitution in
methanol containing the internal standard 1-cyclohexyl-
urido-3-dodecanoic acid (Sigma-Aldrich, St. Louis MO),
and analyzed within 48 hrs to limit monoacylglycerol isom-
erization. Analytes were separated on a 2.1 × 150 mm,
1.7 μm Acquity BEH column on a Waters Acquity UPLC.
Analytes were ionized by electrospray ionization and
detected by multi-reaction monitoring on an API4000
QTRAP (AB-SCIEX, Foster City, CA). Oxylipins and
NAEs/MAGs/LAAs were analyzed in independent in-
jections and ionized in negative and positive modes, re-
spectively. Surrogate recoveries for reported oxylipins
and eCBS were acceptable and stable across all analyt-
ical batches. Isomerization of d8-2-AG was <5% for all
measured samples, and both 1-AG and 2-AG were chro-
matographically resolved (Additional file 2: Figure S1).
Analytes are not reported if the signal-to-noise ratio is <2,
calculated concentrations are below the lowest calibrant,
or apparent surrogate recoveries are below 40%, suggest-
ing either significant loss or suppression of electrospray
ionization. For a complete list of lipid analytes that
were retained for multivariate analysis, see Additional
file 3: Tables S1 and S3.
Total RNA isolation and gene expression analyses
The expression of genes associated with oxylipin and
eCB function was assessed in liver, RP-WAT, and nodose
ganglia to provide a contextual interpretation to diet-
associated differences in plasma mediator tone. RNA
was isolated from RP-WAT fat pads and liver samples
using a Ribopure kit (Applied Biosystems-AM1924) ac-
cording to manufacturer's instructions. Nodose ganglia
mRNA was extracted using micro-Ribopure filters (AB
AM1931). RNA abundance was quantified using a Nano-
Drop ND-1000 Spectrophotometer (NanoDrop Technolo-
gies). cDNA was prepared, and 384-well quantitative PCR
utilizing gene-specific Taqman® primers and FAM-MGB
labeled probes (Assays-on-Demand®, Applied Biosystems)
was conducted as previously described in detail [11], with
the exception that Eukaryotic 18S (ABI) was used as the
endogenous reference gene for all tissues. See Additional
file 3: Tables S2 and S4 for a complete list of gene targets.
Data analysis and statistics
Data treatment prior to analysis included missing value im-
putation if variable sets were >80% complete and normality
transformation, as well as mean center/unit variance scal-
ing prior to multivariate analyses [41]. Imputation was per-
formed independently for each metabolite class using
probabilistic principal components analysis [42]. Missing
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ethanolamides and monoacyl glycerides were imputed
independently. Data were then transformed to normal-
ity using the procedures of Box and Cox [43]. Data im-
putations, transformations, and multivariate analyses
were performed using the Excel Add-In imDEV [44],
which provides a graphical user interface to the R Stat-
istical Computing Environment [45].
Mean differences in plasma lipids and tissue gene ex-
pression were evaluated in Graphpad Prism V.6, after out-
lier exclusion with the false discovery rate based ROUT
Test. If data passed the D’Agostino and Pearson’s omnibus
test for normality, then dietary treatment differences were
assessed by one-way ANOVA with a Tukey post-hoc test.
If data were not normal, the Kruskal-Wallis test was used.
All variables were included for use in multivariate ana-
lyses, including hierarchical cluster analyses and projec-
tion to latent structure discriminate analysis (PLS-DA).
These multivariate analysis approaches highlight groups of
variables which behaved in a similar fashion and provided
group segregations. Hierarchical clusters were based on a
Minkowski distance matrix agglomerated using Ward’s
minimum variance method. PLS-DA was performed using
the SIMPLS algorithm with leave one out cross-validation,
and predictive models were iteratively compared (n = 100)Figure 1 Discriminant analysis clearly segregates dietary treatment gro
model using physiological measurements, 61 plasma lipid metabolites, and m
and nodose ganglia (N-) illustrates differential distribution between DIO mice
calcium + nonfat dry milk (NFDM; green). A plots the latent variable 1 (LV1; X
weights in these axes. Variables were grouped and color coded based on
classes driving group segregation are labeled (for a complete list of varia
cluster with Adiposity Index and 18 carbon acylethanolamides (green clu
HighCa fed mice, along LV1. Conversely, monoacylglycerols cluster with expre
liver, and are elevated in NFDM-fed mice. Body weight, adiposity index, e
inflammatory markers (purple cluster) drive the separation of HighCa fedto those built with data randomly assigned to discriminate
class data.
Results
PLS-DA for COHORT 1
To explore the impact of high-calcium and NFDM on
low abundance signaling lipids during the development
of obesity, a PLS-DA model was generated using plasma
lipid metabolites, tissue mRNA gene expression, and
phenotype parameters. Figure 1A depicts the PLS-DA
scores plot output from this model showing clear separ-
ation of all 3 diet groups. Optimal separation was
achieved along latent variable 1 (LV1) and LV2, and ex-
plained 28% of the variance in the data. Figure 1B is a
loadings plot highlighting the features that best defined
the phenotypic differences between the three diets. Vari-
ables are grouped and color-coded based on a hierarchical
cluster analysis (see Methods) and significant differences
of selected variables from clusters and lipid classes that
drive treatment separation are depicted in Table 1 (for a
complete list of plasma fatty acids analyzed, see Additional
file 3: Table S1). One of the major clusters of variables
driving separation along LV2 included body weight, en-
ergy intake, and inflammatory markers, with HighCa fed
animals displaying increased adiposity and adipose tissue-ups in a mouse model of developing obesity (Cohort 1). A PLS-DA
RNA relative abundance in retroperitoneal adipose tissue (A-), liver (L-),
fed 0.5% calcium (Control; pink), 1.5% calcium (HighCa; yellow), or 1.5%
axis) and 2 (LV2; Y axis) scores for each mouse, while B plots the variable
a hierarchical cluster analysis. Selected variables in clusters and lipid
bles, see Additional file 3: Tables S1 and S2). Plasma fatty acid diols
ster) and are reduced in NFDM-fed mice relative to Control and
ssion of soluble epoxide hydrolase and adipose triglyceride lipase in the
nergy intake, and mRNA abundance of retroperitoneal adipose tissue
mice from NFDM mice and controls in LV2.
Table 1 Concentrations of selected plasma oxylipins and
relative tissue mRNA abundances for oxylipin-relevant
targets in mice with developing obesity
Cohort 1
Control HighCa NFDM
Oxylipins (nM) Mean SEM Mean SEM Mean SEM
∑C18 Diols
15,16-DiHODE 1.68 0.1666a 1.442 0.1114a 0.4278 0.04809b
9,10-DiHOME 4.232 0.08353a 4.192 0.1493a 3.489 0.08201b
12,13-DiHOME 2.525 0.08735a 2.365 0.1339a,b 2.14 0.08462b
9,10-DiHODE 0.8443 0.01388a 0.865 0.02576a 0.7562 0.01735b
∑C20 Diols
8,9-DiHETrE 3.995 0.1728a 3.345 0.1401b 1.536 0.07598c
5,6-DiHETrE 3.634 0.1948a 3.112 0.1064b 0.9325 0.06361c
11,12-DiHETrE 0.7705 0.05849a 0.7053 0.03648a,b 0.5728 0.03826b
∑Epoxides
15(16)-EpODE 2.001 0.128a 1.899 0.1152a 1.419 0.0811b
12,13-EpOME 3.038 0.1481a,b 2.8 0.08468a 3.345 0.07784b
∑Alcohols
5-HEPE 0.7138 0.02803a 0.7739 0.02809a,b 0.8253 0.02512b
mRNA abundance (%)
Adipose
Cyp2j6 100 6.8a 76.2 4.8b 82.6 5.1a,b
Ephx2 100 13.7a 70.4 7.9a,b 62.0 5.3b
Leptin 100 7.2a 90.3 7.5a,b 68.9 5.8b
Trpv1 100 8.4a 73.1 5.8b 67.5 3.2b
Liver
Ephx2 100.0 8.8a 105.8 5.5a 162.8 21.5b
SEM - Standard Error of the Mean.
n = 10/diet treatment group.
For mRNA abundance, expression values are calculated relative to control;
transcript level for CONTROL mice was considered 100%.
Data were tested for normality using D’Agostino and Pearson’s omnibus test.
To test for diet treatment differences, normal data were assessed by one-way
ANOVA with Tukey post-hoc test, non-normal data were assessed
by Kruskal-Wallis.
Values with different superscript letter are significantly different (P < 0.05).
ns - not significant.
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decreases in these factors, relative to controls, as would be
expected from our prior evaluation of these parameters in
the entire cohorts using univariate statistics [17]. A discus-
sion of this obese/inflammatory phenotype has previously
been reported and will, therefore, not be a major focus of
the current paper. Novel results of this model indicate two
distinct lipid classes as dominant drivers of the dietary
group separation (depicted along LV1): 1) diol fatty acids,
products of soluble epoxide hydrolase (sEH) enzyme activ-
ity and 2) monoacylglycerols (MAGs) important to endo-
cannabinoid biochemistry. These results are discussed in
more detail below.1) Plasma diol fatty acid concentrations are decreased in
mice fed a high fat diet rich in NFDM. Compared to
controls, decreases in several species of diol fatty
acids, products of sEH enzyme activity, were detected
in the plasma of NFDM fed mice (Figure 1B, green,
Table 1). Endogenous substrates for sEH include
cytochrome P-450 epoxygenase (CYP)-derived fatty
acids (i.e. epoxyeicosatrienoic acids (EETs)), which
have various bioactive properties. EETs and other
epoxy fatty acids, such as the linoleate-derived
EpOMEs, are readily hydrolyzed by sEH to the corre-
sponding diols (i.e. dihydroxyeicosatrienoic acids
(DHETrEs), dihydroxyoctadecamonoenoic acids
(DiHOMEs), which are generally believed to be less
active metabolites [29,46].
In the current investigation, circulating epoxides were
unaltered by diet, while each of the four C18 diols
measured were decreased in the plasma of NFDM-fed
mice. HighCa did not differ significantly from controls
(Table 1). Additionally, three of the four measured
arachidonate-derived DHETrEs displayed significant
decreases in HighCa fed mice, and even further reduc-
tion in NFDM fed mice, compared to controls. Further,
the abundance of soluble epoxide hydrolase gene
(Ephx2) mRNA, was significantly increased and de-
creased in the liver and RP-WAT of NFDM-fed mice,
respectively, compared to controls (Table 1).
2) Several species of monoacylglycerol (MAG) are
elevated in the plasma of mice fed a high fat diet rich
in NFDM. According to the multivariate statistical
model, plasma levels of 2-AG, a known ligand for the
CB1 receptor, and other structurally-related MAGs
(arachidonate-derived 1-AG, linoleate-derived 1-LG
and 2-LG, and oleate-derived 1-OG and 2-OG) were
contributing variables defining the separation between
diet treatment groups and in particular NFDM from
the other diets (Figure 1B, light blue, Table 2). PCR re-
sults indicate the expression levels of cannabinoid re-
ceptor genes Cnr1 and Cnr2 were down-regulated in
the RP-WAT of NFDM-fed animals compared to con-
trols (Table 2) and were not detected in liver (data not
shown). Interestingly, monoacylglycerol lipase (Mgll),
an enzyme responsible for the breakdown of 2-AG,
was also down-regulated in RP-WAT of NFDM fed
mice, but not significantly from controls. In contrast,
plasma levels for the more potent but less abundant
endogenous CB1 ligand anandamide (AEA), as well as
RP-WAT mRNA abundance of the AEA catabolic en-
zyme fatty acid amide hydrolase (Faah), were not dif-
ferent among the three diets (AEA concentration:
CONTROL, 2.467 ± 0.297; HighCa, 2.512 ± 0.242,
NFDM, 2.111 ± 0.216 nM) (Faah relative mRNA
abundance: CONTROL 100 ± 4.4, HighCa, 87.5 ± 6.1,
NFDM, 83.3 ± 11.7%) (See Additional file 3: Tables S1
Table 2 Concentrations of selected plasma
monoacylglycerols (MAG), N-acylamides (NAE), and relative
tissue mRNA abundances for endocannabinoid-relevant





Mean SEM Mean SEM Mean SEM
∑MAG
1-AG 2.758 0.1366a 3.096 0.1573a,b 3.599 0.1214b
2-AG 5.718 0.3126a 5.553 0.3529a 8.841 0.3825b
1-LG 7.147 0.1388a 7.606 0.1195a 8.369 0.228b
2-LG 7.929 0.1191a 8.235 0.09149a 9.005 0.1418b
1-OG 7.626 0.09071a 8.196 0.1491a,b 8.287 0.2314b
2-OG 25.51 2.242a 33.74 2.376a,b 37.31 4.725b
∑NAE
DGLEA 0.4023 0.04208a,b 0.437 0.04364a 0.2798 0.02968b
LEA 22.84 12.06a 7.488 3.736a 2.368 1.181b
mRNA abundance (%)
Adipose
Cnr1 100 9.8a 91.3 10.8a,b 63.8 3.7b
Cnr2 100 13.9a 130.3 13.0a 54.3 10.7b
Mgll 100 10.4a 71.1 5.8b 78.2 5.3a,b
Liver
Pnpla2 100 8.4a 254.9 49.8b 234.2 42.7a,b
SEM - Standard Error of the Mean.
n = 10/diet treatment group.
For mRNA abundance, expression values are calculated relative to control;
transcript level for CONTROL mice was considered 100%.
Data were tested for normality using D’Agostino and Pearson’s omnibus test.
To test for diet treatment differences, normal data were assessed by one-way
ANOVA with Tukey post-hoc test, non-normal data were assessed by Kruskal-Wallis.
Values with different superscript letter are significantly different (P < 0.05).
ns - not significant.
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N-acyl ethanolamines (NAE) structurally related to
AEA in the plasma of NFDM-fed animals, dihomoga-
malinoleaoylethanolamide (DGLEA) and linoleoy-
lethanolamide (LEA) (Table 2).
PLS-DA for COHORT 2
To explore the effect of high-calcium and dairy in the con-
text of pre-existing obesity, mice in Cohort 2 underwent a
pre-fattening period for 12 weeks before being randomized
and placed on one of three experimental diets for an add-
itional 8 weeks. As previously reported, pre-fattened DIO
mice fed NFDM had significantly improved glucose
homeostasis and markedly lower liver triglycerides, despite
minimal differences in body weight, adiposity, and adipose
tissue inflammation between the three diet treatment
groups [17,18]. In the current investigation, the impact of
high-calcium and dairy on low abundance signaling lipids
in pre-fattened mice was explored using a PLS-DA modelsimilar to Cohort 1. Figure 2A depicts the PLS-DA scores
plot output from this model. Separation of the NFDM
group was evident along LV1 (16% explained variance).
Compared to Cohort 1, there was similar directionality in
the group separations; however, controls and HighCa fed
mice were not completely distinguished. Figure 2B is a
loadings plot indicating selected features that defined
the phenotypic differences between the three diets. Var-
iables are color-coded by cluster analysis and significant
differences of selected variables from clusters and lipid
classes that drive treatment separation are depicted in
Table 3. (For a complete list of plasma fatty acids analyzed,
see Additional file 3: Table S3). Although body weight and
adipose inflammation appear to contribute somewhat to
the separation of groups, it is to a much lesser extent than
as seen in Cohort 1 where body weight and inflammatory
differences were much more robust, as previously re-
ported for these conditions [18].
Similar to Cohort 1, the lipid variables contributing
most to the separation between diets were again diol
fatty acids and MAGs:
1) Plasma diol fatty acid concentrations are decreased in
NFDM fed mice with pre-existing obesity. Compared to
controls, there was a trend in decreasing C18 diols; how-
ever, only 9,10-DiHOME and 15,16-DiHODE reached
significance (Table 3). We observed a significant decrease
in three of the four measured C20 arachidonate-derived
vicinal diols in NFDM fed animals, while HighCa fed
animals were not different from controls. Unlike Cohort
1, mRNA abundance for Ephx2 in both the liver and
adipose was unaffected by diet in Cohort 2.
2) MAG concentrations are elevated in the plasma of
NFDM fed animals with pre-existing obesity. The
increases in plasma MAGs seen in this cohort were
much more modest (10-20%) than the increases seen
in Cohort 1, with only 2-AG, 1-LG and 2-LG reaching
statistical significance (Table 4). Nevertheless,
as a group these metabolites were important
discriminating variables distinguishing the NFDM
group from the Control and HighCa groups. PCR
results in RP-WAT did not show significant
differences in mRNA abundances for Cnr1 or Cnr2
(Table 4) or Faah (Additional file 3: Table S4);
however, Mgll was significantly increased in NFDM
fed animals, compared to controls. Plasma levels of all
NAEs measured did not differ among the three diets.
Discussion
A diet rich in dairy has been associated with improvements
in body composition, metabolic disease risk markers and
inflammatory status; however, the mechanisms by which
dairy exerts its effects are still being elucidated. In the
current study, we identified unique profiles of oxylipins
Figure 2 Discriminant analysis clearly segregates dietary treatment groups in a mouse model of pre-existing obesity (Cohort 2). In a
pre-existing obesity mouse model (control DIO diet for 12 weeks), a PLS-DA model using 61 plasma lipid metabolites, physiologic measurements,
and mRNA abundance in retroperitoneal adipose tissue (A-), liver (L-), and nodose ganglia (N-) illustrates differential distribution between dietary
treatment groups. A plots the latent variable 1 (LV1; X axis) and 2 (LV2; Y axis) scores for each mouse fed 0.5% calcium (Control; pink) and 1.5%
calcium (HighCa; yellow) or 1.5% calcium + nonfat dry milk (NFDM; green), while B plots the variable weights in these axes. Variables were grouped
and color coded based on a hierarchical cluster analysis. Selected variables from clusters and lipid classes driving group segregation are labeled (for a
complete list of variables, see Additional file 3: Tables S3 and S4). Plasma fatty acid diols cluster together (green cluster) and are reduced in NFDM-fed
mice relative to Control and HighCa-fed mice. Conversely, monoacylglycerols cluster with a variety of adipose, liver and nodose ganglia gene
expression levels (purple cluster), and are elevated in the NFDM-fed mice.
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diet rich in NFDM. As previously reported, these NFDM
fed animals displayed decreased adiposity, markedly re-
duced steatosis, and lower adipose inflammation in com-
parison to control/high-calcium, soy protein based high fat
diets [17,18]. The results described herein highlight that
these phenotypic differences may be associated with alter-
ations in circulating bioactive lipids.
Biosynthesis of oxylipins is catalyzed by cyclo-oxygenase
(COX), lipoxygenase (LOX), and cytochrome p450 (CYP)
enzymes [29]. The bioactive products of these pathways
have broad cellular effects on vascular [47], hepatic [48], and
adipose physiology [32], and, depending on the specific me-
tabolites involved, can exert both pro-inflammatory and
anti-inflammatory effects. In the current investigation, diet-
ary treatment resulted in distinct changes to patterns of
plasma lipids emanating from the CYP epoxygenase path-
ways, but not LOX and COX pathways. Specifically, mice
fed a NFDM based diet displayed decreases in several spe-
cies of diol fatty acids, products of soluble epoxide hydrolase
(sEH) enzyme activity, compared to controls or mice fed
high calcium alone. These effects were observed in two sep-
arate cohorts of mice, each with disparate weight outcomes
in response to NFDM and HighCa, suggesting that changes
in diol biochemistry were unique to the NFDM diet and
weight/adiposity-independent.The major CYP-derived products include epoxide fatty
acids (i.e. arachidonate-derived epoxyeicosatrienoic acids
(EETs)). Recent evidence suggests EETS have beneficial
effects on adipose and liver insulin sensitivity through
the reduction of ER stress [49,50], and that DHETs,
products of EET hydrolysis by sHE, exert their own op-
posing activity (DHETs increase ER stress and attenuate
insulin sensitivity). Our findings are consistent with the
role for epoxide/sEH/diol activity in mediating inflam-
mation and insulin signaling. While epoxides were simi-
lar across dietary treatment groups, decreased plasma
diols observed in the plasma of NFDM fed mice were as-
sociated with this group’s improved glucose tolerance,
dampened inflammation, and reduced liver steatosis, both
in developing obesity (Cohort 1) [17] and pre-existing
obesity (Cohort 2) [18].
The mechanism by which NFDM decreases plasma di-
ols is unclear, but could result from direct dietary effects
on relevant biochemical pathways and substrates flowing
through the CYP epoxygenase/sEH pathways, or proceed
secondary to metabolic and inflammatory phenotypes
associated with these diets. While fatty acid composition
was the same for all experimental diets, other compo-
nents of dairy, such as dairy protein, may alter appetite-
regulating hormones [24], thereby decreasing total food
intake and overall total fatty acid substrates. However,
Table 3 Concentrations of selected plasma oxylipins and
relative tissue mRNA abundances for oxylipin-relevant





Mean SEM Mean SEM Mean SEM
∑C18 Diols
9,10-DiHOME 2.782 0.1526a 2.749 0.1174a 2.183 0.07732b
12,13-DiHOME 1.813 0.1115ns 1.752 0.07892ns 1.516 0.07118ns
9,10-DiHODE 0.04739 0.01185a,b 0.06502 0.0143a 0.01457 0.009056b
15,16-DiHODE 1.224 0.1558a 1.192 0.07191a 0.4152 0.04656b
∑C20 Diols
8,9-DiHETrE 3.176 0.1345a 2.531 0.1684b 1.054 0.07053c
5,6-DiHETrE 2.871 0.129a 2.332 0.1745a 0.7654 0.157b
11,12-DiHETrE 0.753 0.04288a 0.7909 0.0363a 0.6191 0.03119b
14,15-DiHETrE 0.9577 0.03963a,b 1.05 0.0584a 0.88 0.06521b
14,15-DiHETE 0.9577 0.03963a,b 1.05 0.0584a 0.88 0.06521b
17,18-DiHETE 1.691 0.08384a,b 1.883 0.07553a 1.56 0.03399b
∑C22 Diols
19,20-DiHDoPE 2.711 0.2254a,b 3.41 0.2376a 2.242 0.2042b
∑Epoxides
15(16)-EpODE 1.524 0.1816a 1.501 0.1288a 0.9132 0.07219b
mRNA abundance (%)
Adipose
Cyp2j6 100 9.5a 123.2 14.8a 218.1 29.8b
Ephx2 100 15.7a,b 79.55 13.0a 144.6 17.3b
Leptin 100 151.3ns 48.84 59.1ns 15.4 18.7ns
Trpv1 100 9.3ns 99.7 9.1ns 139.5 19.7ns
Liver
Ephx2 100 6.1ns 98.45 7.0ns 123.0 10.9ns
SEM - Standard Error of the Mean.
n = 10/diet treatment group; For mRNA abundance, expression values are
calculated relative to control; transcript level for CONTROL mice was
considered 100%.
Data were tested for normality using D’Agostino and Pearson’s omnibus test.
To test for diet treatment differences, normal data were assessed by one-way
ANOVA with Tukey post-hoc test, non-normal data were assessed by Kruskal-Wallis.
Values with different superscript letter are significantly different (P < 0.05).
ns - not significant.
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able in the PLS-DA model, did not cluster with diol fatty
acids, and was not reduced in NFDM-fed mice [17,18].
Alternatively, diet-associated signals or the attenuated
obesity phenotype in NFDM mice could have reduced
tissue sEH expression and/or activity. It has been previ-
ously reported that sEH protein is increased in adipose
and liver of DIO mice and obese humans [50], presum-
ably decreasing the beneficial activity of epoxides. In the
current investigation, Epxh2 (sEH) mRNA expression
was elevated in the liver and reduced in the adipose of
NFDM fed animals during developing obesity, but thesechanges were not apparent in the presence of pre-
existing obesity. However, changes in sEH activity have
been reported despite no changes in mRNA expression
[51]. Furthermore, it is unclear how plasma pools of oxyli-
pins reflect tissue specific enzyme activity, and whether
paracrine activity is more important to the phenotype ob-
served. Future studies will be needed to explore if NFDM
alters tissue-specific diol production and sEH activity or
protein abundance. Nevertheless, we have demonstrated
for the first time that circulating oxylipins are altered in
DIO mice fed a diet rich in NFDM, a diet that improves
inflammatory status and glucose homeostasis.
In addition to possible effects of oxylipin changes in
supporting NFDM-associated phenotypes, the endocan-
nabinoid system and structurally-related analogs were
considered due to their deep involvement in the control
of food intake and energy homeostasis [52]. In this study,
several species of MAG, including 2-AG, increased in the
plasma of DIO mice fed NFDM compared to the Control
or HighCa diets, under the conditions of both developing
obesity and pre-existing obesity. 2-AG has been shown to
be a more efficacious cannabinoid receptor agonist than
AEA [53], while other 2-MAGS have been shown to
potentiate the activity of eCBs (i.e. 2-LG) [54] or have
GPR119 agonist activity (i.e. 2-OG) [55]. Others have
reported that 2-AG is increased in peripheral tissues of
animals fed a high-fat diet (HFD) [56,57], and circulating
2-AG levels positively correlate with BMI and intra-
abdominal adiposity in humans [58,59], although this
observation has not been universal [40]. An association
between eCB tone and obesity has been hypothesized to
exacerbate obesity-related dysmetabolic conditions by in-
creasing food intake and liver fatty acid synthesis through
cannabinoid type-1 (CB1) receptor signaling [36,52,60].
However, in the current study, increases in circulating
2-AG levels in NFDM fed animals were concurrent with
markedly reduced liver steatosis, even in Cohort 2 where
body weight differences from Control animals were
minimal [17,18]. Similar findings were reported in a
mouse model where tissue levels of 2-AG were artificially
elevated by utilizing a monoglyceride lipase (Mgl) global
knockout, the primary degrading enzyme for 2-AG [61].
These animals did not demonstrate the expected hyper-
phagia and increased weight gain when fed a high fat diet
and exhibited improved insulin sensitivity and consider-
ably less liver steatosis, similar to NFDM-fed mice seen
herein. The authors also reported desensitization in liver
CB1 receptor signaling in Mgl knockouts. Although liver
CB1 and CB2 mRNA were not detected in the present
study, we did observe a significant decrease in CB1 and
CB2 receptor mRNA in the RP WAT of NFDM fed
animals, at least in Cohort 1 where increases in 2-AG
were much more robust. Decreased adipose CB1 receptor
gene expression was also associated with increased
Table 4 Concentrations of selected plasma
monoacylglycerols (MAG), N-acylamides (NAE), and relative
tissue mRNA abundances for endocannabinoid-relevant





Mean SEM Mean SEM Mean SEM
∑MAG
1-AG 2.922 0.1194ns 3.132 0.2386ns 3.437 0.2354ns
2-AG 5.44 0.07841a 5.437 0.06266a 5.919 0.1294b
1-LG 4.964 0.222a 5.295 0.1451a,b 6.067 0.291b
2-LG 8.196 0.1433a 8.293 0.09063a 9.149 0.1696b
1-OG 7.399 0.1517ns 7.829 0.1807ns 7.828 0.2093ns
2-OG 8.197 0.1308ns 8.553 0.1325ns 8.665 0.1947ns
∑NAE
AEA 2.093 0.1251ns 2.81 0.2002ns 1.744 0.1747ns
LEA 20.92 1.406ns 22.21 1.996ns 16.22 1.885ns
mRNA abundance (%)
Adipose
Mgll 100 12.0a 73.5 10.9a 162.9 19.3b
Cnr1 100 15.4ns 91.2 13.7ns 130.2 20.6ns
Cnr2 100 15.9ns 140.8 18.7ns 85.08 14.1ns
Pnpla2 100 13.5a,b 68.7 8.8a 132.9 17.7b
Nodose
Cnr1 100 10.2a,b 88.7 6.5a 117.6 7.1b
SEM - Standard Error of the Mean.
n = 10/diet treatment group.
For mRNA abundance, expression values are calculated relative to control;
transcript level for CONTROL mice was considered 100%.
Data were tested for normality using D’Agostino and Pearson’s omnibus test.
To test for diet treatment differences, normal data were assessed by one-way
ANOVA with Tukey post-hoc test, non-normal data were assessed
by Kruskal-Wallis.
Values with different superscript letter are significantly different (P < 0.05).
ns - not significant.
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[58]. While speculative, this raises the possibility that, in
NFDM-fed mice, negative feedback regulation of canna-
binoid receptor signaling by elevated 2-AG contributed to
the lean phenotype.
In addition to 2-AG, several other species of MAG were
elevated in the plasma of NFDM fed mice, prompting us
to quantify the mRNA abundances of enzymes involved in
synthesis (fatty acid liberation via lipolysis) and degrad-
ation of these metabolites in RP-WAT, liver, and nodose
ganglia (containing vagal afferent neurons), sites that rep-
resent tissues responsive to endocannabinoid actions. In
our multivariate model, mRNA abundances for these tar-
gets weakly contributed to the separation of treatment
groups. However, it is acknowledged that mRNA expres-
sion may not reflect protein levels or enzyme activity.
Alternatively, elevations of plasma 2-AG observed heremay be a regulatory response to anti-inflammatory signals
stemming from the NFDM diet. Endocannabinoids, in-
cluding 2-AG, exert immunomodulatory effects across
many different cell types and tissues [62], and it has been
reported that plasma 2-AG is decreased under acute in-
flammatory exposure [63].
Furthermore, enzyme activity and eCB signaling in
tissue sites not sampled herein may contribute to the
plasma pool of metabolites or drive the observed pheno-
type. For instance, intestinal eCB signaling influences food
intake via vagal afferents [64-66] and models of intestinal
inflammation increase eCB tone [67,68]. Also, cross-talk
between the eCB system and the gut microbiome can alter
adipose physiology [69] and recent studies demonstrated
that administration of Akkermansia muciniphila, a bacter-
ium associated with an improved metabolic profile, in-
creased intestinal levels of the monoglycerols 2-AG, 2-OG
and 2-PG [70]. Intriguingly, we have detected significant
differences in the microbiome composition of the mice
fed NFDM compared to the other dietary groups [71],
raising the possibility that intestinal alterations are respon-
sible for elevations in systemic 2-AG and possibly other
metabolites.
It is important to address whether the distinct pattern of
lipid metabolites seen here is due to a direct dietary effect
or a secondary consequence of the phenotype. Studies
addressing dietary influences on oxylipins and eCBs
primarily focus on amount and composition of dietary fat
[38,72,73]. In the current study, the source and macro-
nutrient content of fat were identical across treatment
groups and was presumably not a driver in the treatment
associated phenotypes. Furthermore, high-calcium alone
is not sufficient to exert the effects seen here, since
HighCa and NFDM fed animals, whom both received
1.5% calcium in their diets, discriminated independently
from one another in our multivariate models. In future
studies it will be interesting to determine if NFDM effects
on lipid and enzyme phenotypes, reported herein, are
modulated by altering dietary Ca intake. Regardless, there
is evidence that the lipidomic patterns seen here are influ-
enced by diet and are not simply a consequence of a lean
or obese phenotype. First, lipid metabolites that best dis-
criminate treatment differences in our multivariate model
cluster independently from body weight, adiposity, adipose
inflammatory markers, and food intake. Second, the
pattern of discriminating factors observed in our model
was observed in both Cohort 1 (developing obesity) and
Cohort 2 (pre-existing obesity) studies despite markedly
different feeding paradigms and body weight outcomes.
Conclusion
In summary, this study illustrates that differences in
bioactive lipid profiles are associated with metabolic and
inflammatory phenotypes seen in NFDM mice, which
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stasis, avoidance of steatosis and dampened inflamma-
tory markers. NFDM fed mice showed a decrease
in plasma diols which is consistent with a possible role
for epoxide/diol balance in regulating insulin sensitivity
and inflammation. Furthermore, increases in circulating
2-AG seen in NFDM may constitute an adaptive mech-
anism to increase food intake in response to other diet-
ary regulatory inputs that drive the lean phenotype and
reduced feed efficiency observed in these mice. Future
studies are necessary to reveal the exact mechanisms by
which these lipidomic shifts occur, and to elucidate
whether these lipid metabolites participate in the
metabolic effects of dairy-rich diets.
Additional files
Additional file 1: Table S5. UPLC/MS-MS parameters of oxylipins and
endocannabinoids measured in plasma.
Additional file 2: Figure S1. Representative chromatograms of 2-AG
and 1-AG resolution from a single plasma sample and low level calibration
standard.
Additional file 3: Table S1. Mean concentrations (nM) of plasma fatty
acids in mice with developing obesity. Table S2. Relative mRNA
abundances and physiological measurments in mice with developing
obesity. Table S3. Mean concentrations (nM) of plasma fatty acids in
mice with pre-existing obesity. Table S4. Relative mRNA abundances and
physiological measurments in mice with pre-exisiting obesity.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
TND, AHK, APT, SHA conducted animal model research and/or sample
analyses; TND, AHK, JWN conducted statistical analysis; TND, AHK, JWN, SHA
interpreted results; and TND drafted the manuscript with edits from all authors.
All authors read and approved the final manuscript.
Acknowledgements
The authors would like to thank the UC Davis vivarium staff in helping care
for the animals. Supported in part by intramural USDA-ARS Projects 5306-
51530-016-00D and 5306-51530-019-00 and the National Dairy Council (grant
administered by the Dairy Research Institute). USDA is an equal opportunity
provider and employer.
Author details
1Graduate Group in Nutritional Biology, University of California, Davis, USA.
2Current address: Center for Computational and Integrative Biology,
Massachusetts General Hospital, Boston, MA, USA. 3Current Address: Larry L.
Hillblom Islet Research Center, University of California, Los Angeles, David
Geffen School of Medicine, Los Angeles, CA, USA. 4Obesity & Metabolism
Research Unit, USDA-Agricultural Research Service Western Human Nutrition
Research Center, Davis, CA, USA. 5Department of Nutrition, University of
California, Davis, USA. 6USDA-ARS Western Human Nutrition Research Center,
430 W. Health Sciences Dr, Davis, CA 95616, USA.
Received: 2 November 2013 Accepted: 6 May 2014
Published: 30 May 2014
References
1. Fain JN: Release of interleukins and other inflammatory cytokines by
human adipose tissue is enhanced in obesity and primarily due to the
nonfat cells. Vitam Horm 2006, 74:443–477.2. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr:
Obesity is associated with macrophage accumulation in adipose tissue.
J Clin Invest 2003, 112:1796–1808.
3. Olefsky JM, Glass CK: Macrophages, inflammation, and insulin resistance.
Annu Rev Physiol 2010, 72:219–246.
4. Zeyda M, Stulnig TM: Obesity, inflammation, and insulin resistance–a
mini-review. Gerontology 2009, 55:379–386.
5. Browning LM, Krebs JD, Magee EC, Fruhbeck G, Jebb SA: Circulating
markers of inflammation and their link to indices of adiposity. Obes Facts
2008, 1:259–265.
6. Teegarden D: Calcium intake and reduction in weight or fat mass. J Nutr
2003, 133:249S–251S.
7. Zemel MB: The role of dairy foods in weight management. J Am Coll Nutr
2005, 24:537S–546S.
8. Zemel MB, Sun X, Sobhani T, Wilson B: Effects of dairy compared with soy
on oxidative and inflammatory stress in overweight and obese subjects.
Am J Clin Nutr 2010, 91:16–22.
9. Labonte ME, Couture P, Richard C, Desroches S, Lamarche B: Impact of
dairy products on biomarkers of inflammation: a systematic review of
randomized controlled nutritional intervention studies in overweight
and obese adults. Am J Clin Nutr 2013, 97:706–717.
10. Chen M, Pan A, Malik VS, Hu FB: Effects of dairy intake on body weight
and fat: a meta-analysis of randomized controlled trials. Am J Clin Nutr
2012, 96:735–747.
11. Thomas AP, Dunn TN, Oort PJ, Grino M, Adams SH: Inflammatory
phenotyping identifies CD11d as a gene markedly induced in white
adipose tissue in obese rodents and women. J Nutr 2011, 141:1172–1180.
12. Zemel MB, Sun X: Dietary calcium and dairy products modulate
oxidative and inflammatory stress in mice and humans. J Nutr 2008,
138:1047–1052.
13. Sun X, Zemel MB: Calcitriol and calcium regulate cytokine production
and adipocyte-macrophage cross-talk. J Nutr Biochem 2008, 19:392–399.
14. Sun X, Zemel MB: Role of uncoupling protein 2 (UCP2) expression and
1alpha, 25-dihydroxyvitamin D3 in modulating adipocyte apoptosis.
FASEB J 2004, 18:1430–1432.
15. Giulietti A, van Etten E, Overbergh L, Stoffels K, Bouillon R, Mathieu C:
Monocytes from type 2 diabetic patients have a pro-inflammatory
profile. 1,25-Dihydroxyvitamin D(3) works as anti-inflammatory. Diabetes
Res Clin Pract 2007, 77:47–57.
16. Parikh SJ, Yanovski JA: Calcium intake and adiposity. Am J Clin Nutr 2003,
77:281–287.
17. Thomas AP, Dunn TN, Drayton JB, Oort PJ, Adams SH: A high calcium diet
containing nonfat dry milk reduces weight gain and associated adipose
tissue inflammation in diet-induced obese mice when compared to high
calcium alone. Nutr Metab (Lond) 2012, 9:3.
18. Thomas AP, Dunn TN, Drayton JB, Oort PJ, Adams SH: A dairy-based high
calcium diet improves glucose homeostasis and reduces steatosis in the
context of preexisting obesity. Obesity (Silver Spring) 2013, 21:E229–E235.
19. Bharadwaj S, Naidu TA, Betageri GV, Prasadarao NV, Naidu AS:
Inflammatory responses improve with milk ribonuclease-enriched
lactoferrin supplementation in postmenopausal women. Inflamm Res
2010, 59:971–978.
20. Chrysant SG, Chrysant GS: An update on the cardiovascular pleiotropic effects
of milk and milk products. J Clin Hypertens (Greenwich) 2013, 15:503–510.
21. Chatterton DE, Nguyen DN, Bering SB, Sangild PT: Anti-inflammatory
mechanisms of bioactive milk proteins in the intestine of newborns. Int J
Biochem Cell Biol 2013, 45:1730–1747.
22. Negro M, Giardina S, Marzani B, Marzatico F: Branched-chain amino acid
supplementation does not enhance athletic performance but affects
muscle recovery and the immune system. J Sports Med Phys Fitness 2008,
48:347–351.
23. Bruckbauer A, Zemel MB: Effects of dairy consumption on SIRT1 and
mitochondrial biogenesis in adipocytes and muscle cells. Nutr Metab
(Lond) 2011, 8:91.
24. Bendtsen LQ, Lorenzen JK, Bendsen NT, Rasmussen C, Astrup A: Effect of
dairy proteins on appetite, energy expenditure, body weight, and
composition: a review of the evidence from controlled clinical trials. Adv
Nutr 2013, 4:418–438.
25. Graf S, Egert S, Heer M: Effects of whey protein supplements on
metabolism: evidence from human intervention studies. Curr Opin Clin
Nutr Metab Care 2011, 14:569–580.
Dunn et al. Nutrition & Metabolism 2014, 11:24 Page 11 of 12
http://www.nutritionandmetabolism.com/content/11/1/2426. Pal S, Ellis V, Dhaliwal S: Effects of whey protein isolate on body
composition, lipids, insulin and glucose in overweight and obese
individuals. Br J Nutr 2010, 104:716–723.
27. Nilsson M, Holst JJ, Bjorck IM: Metabolic effects of amino acid mixtures
and whey protein in healthy subjects: studies using glucose-equivalent
drinks. Am J Clin Nutr 2007, 85:996–1004.
28. Silvestri C, Di Marzo V: The endocannabinoid system in energy
homeostasis and the etiopathology of metabolic disorders. Cell Metab
2013, 17:475–490.
29. Luo P, Wang MH: Eicosanoids, beta-cell function, and diabetes.
Prostaglandins Other Lipid Mediat 2011, 95:1–10.
30. Kalupahana NS, Claycombe KJ, Moustaid-Moussa N: (n-3) Fatty acids
alleviate adipose tissue inflammation and insulin resistance: mechanistic
insights. Adv Nutr 2011, 2:304–316.
31. Shearer GC, Newman JW: Impact of circulating esterified eicosanoids and
other oxylipins on endothelial function. Curr Atheroscler Rep 2009, 11:403–410.
32. Martinez-Clemente M, Claria J, Titos E: The 5-lipoxygenase/leukotriene
pathway in obesity, insulin resistance, and fatty liver disease. Curr Opin
Clin Nutr Metab Care 2011, 14:347–353.
33. Vettor R, Pagano C: The role of the endocannabinoid system in
lipogenesis and fatty acid metabolism. Best Pract Res Clin Endocrinol Metab
2009, 23:51–63.
34. Liu J, Zhou L, Xiong K, Godlewski G, Mukhopadhyay B, Tam J, Yin S, Gao P,
Shan X, Pickel J: Hepatic cannabinoid receptor-1 mediates diet-induced
insulin resistance via inhibition of insulin signaling and clearance in
mice. Gastroenterology 2012, 142:1218–1228. e1211.
35. Di Marzo V: "De-liver-ance" from CB(1): a way to counteract insulin
resistance? Gastroenterology 2012, 142:1063–1066.
36. Di Marzo V, Matias I: Endocannabinoid control of food intake and energy
balance. Nat Neurosci 2005, 8:585–589.
37. Kim J, Li Y, Watkins BA: Endocannabinoid signaling and energy
metabolism: a target for dietary intervention. Nutrition 2011, 27:624–632.
38. Banni S, Di Marzo V: Effect of dietary fat on endocannabinoids and
related mediators: consequences on energy homeostasis, inflammation
and mood. Mol Nutr Food Res 2010, 54:82–92.
39. Shearer GC, Harris WS, Pedersen TL, Newman JW: Detection of omega-3
oxylipins in human plasma and response to treatment with omega-3
acid ethyl esters. J Lipid Res 2010, 51:2074–2081.
40. Grapov D, Adams SH, Pedersen TL, Garvey WT, Newman JW: Type 2
diabetes associated changes in the plasma non-esterified fatty acids,
oxylipins and endocannabinoids. PLoS One 2012, 7:e48852.
41. van den Berg RA, Hoefsloot HC, Westerhuis JA, Smilde AK, van der Werf MJ:
Centering, scaling, and transformations: improving the biological
information content of metabolomics data. BMC Genomics 2006, 7:142.
42. Wang C, Wang W: Links between PPCA and subspace methods for
complete Gaussian density estimation. IEEE Trans Neural Netw 2006,
17:789–792.
43. Box GEP, Cox DR: An analysis of transformations. J Royal Stat Soc 1964,
26:211–252.
44. Grapov D, Newman JW: imDEV: a graphical user interface to R
multivariate analysis tools in Microsoft Excel. Bioinformatics 2012,
28:2288–2290.
45. R Core Team, R Foundation for Statistical Computing: R: A Language and
Environment for Statistical Computing. http://www.R-project.org, Vienna:
2014.
46. Newman JW, Morisseau C, Hammock BD: Epoxide hydrolases: their roles
and interactions with lipid metabolism. Prog Lipid Res 2005, 44:1–51.
47. Wong MS, Vanhoutte PM: COX-mediated endothelium-dependent
contractions: from the past to recent discoveries. Acta Pharmacol Sin
2010, 31:1095–1102.
48. Sacerdoti D, Gatta A, McGiff JC: Role of cytochrome P450-dependent
arachidonic acid metabolites in liver physiology and pathophysiology.
Prostaglandins Other Lipid Mediat 2003, 72:51–71.
49. Luria A, Bettaieb A, Xi Y, Shieh GJ, Liu HC, Inoue H, Tsai HJ, Imig JD, Haj FG,
Hammock BD: Soluble epoxide hydrolase deficiency alters pancreatic
islet size and improves glucose homeostasis in a model of insulin
resistance. Proc Natl Acad Sci U S A 2011, 108:9038–9043.
50. Bettaieb A, Nagata N, AbouBechara D, Chahed S, Morisseau C, Hammock
BD, Haj FG: Soluble epoxide hydrolase deficiency or inhibition attenuates
diet-induced endoplasmic reticulum stress in liver and adipose tissue.
J Biol Chem 2013, 288:14189–14199.51. De Taeye BM, Morisseau C, Coyle J, Covington JW, Luria A, Yang J, Murphy SB,
Friedman DB, Hammock BB, Vaughan DE: Expression and regulation of
soluble epoxide hydrolase in adipose tissue. Obesity (Silver Spring) 2010,
18:489–498.
52. Matias I, Di Marzo V: Endocannabinoids and the control of energy
balance. Trends Endocrinol Metab 2007, 18:27–37.
53. Gonsiorek W, Lunn C, Fan X, Narula S, Lundell D, Hipkin RW:
Endocannabinoid 2-arachidonyl glycerol is a full agonist through human
type 2 cannabinoid receptor: antagonism by anandamide. Mol Pharmacol
2000, 57:1045–1050.
54. Ben-Shabat S, Fride E, Sheskin T, Tamiri T, Rhee MH, Vogel Z, Bisogno T,
De Petrocellis L, Di Marzo V, Mechoulam R: An entourage effect: inactive
endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol
cannabinoid activity. Eur J Pharmacol 1998, 353:23–31.
55. Hansen HS, Rosenkilde MM, Holst JJ, Schwartz TW: GPR119 as a fat sensor.
Trends Pharmacol Sci 2012, 33:374–381.
56. Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, Cervino C,
Petrosino S, Hoareau L, Festy F, Pasquali R, Roche R, Maj M, Pagotto U,
Monteleone P, Di Marzo V: Regulation, function, and dysregulation of
endocannabinoids in models of adipose and beta-pancreatic cells and in
obesity and hyperglycemia. J Clin Endocrinol Metab 2006, 91:3171–3180.
57. Matias I, Petrosino S, Racioppi A, Capasso R, Izzo AA, Di Marzo V:
Dysregulation of peripheral endocannabinoid levels in hyperglycemia
and obesity: Effect of high fat diets. Mol Cell Endocrinol 2008,
286:S66–S78.
58. Bluher M, Engeli S, Kloting N, Berndt J, Fasshauer M, Batkai S, Pacher P,
Schon MR, Jordan J, Stumvoll M: Dysregulation of the peripheral and
adipose tissue endocannabinoid system in human abdominal obesity.
Diabetes 2006, 55:3053–3060.
59. Cote M, Matias I, Lemieux I, Petrosino S, Almeras N, Despres JP, Di Marzo V:
Circulating endocannabinoid levels, abdominal adiposity and related
cardiometabolic risk factors in obese men. Int J Obes (Lond) 2007,
31:692–699.
60. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S,
Harvey-White J, Mackie K, Offertaler L, Wang L, Kunos G: Endocannabinoid
activation at hepatic CB1 receptors stimulates fatty acid synthesis and
contributes to diet-induced obesity. J Clin Invest 2005, 115:1298–1305.
61. Taschler U, Radner FP, Heier C, Schreiber R, Schweiger M, Schoiswohl G,
Preiss-Landl K, Jaeger D, Reiter B, Koefeler HC, Wojciechowski J, Theussl C,
Penninger JM, Lass A, Haemmerle G, Zechner R, Zimmermann R:
Monoglyceride lipase deficiency in mice impairs lipolysis and
attenuates diet-induced insulin resistance. J Biol Chem 2011,
286:17467–17477.
62. Alhouayek M, Masquelier J, Muccioli GG: Controlling 2-arachidonoylglycerol
metabolism as an anti-inflammatory strategy. Drug Discov Today 2014,
19:295–304.
63. Balvers MG, Verhoeckx KC, Bijlsma S, Rubingh CM, Meijerink J, Wortelboer
HM, Witkamp RF: Fish oil and inflammatory status alter the n-3 to n-6
balance of the endocannabinoid and oxylipin metabolomes in mouse
plasma and tissues. Metabolomics 2012, 8:1130–1147.
64. Storr MA, Sharkey KA: The endocannabinoid system and gut-brain
signalling. Curr Opin Pharmacol 2007, 7:575–582.
65. Burdyga G, Lal S, Varro A, Dimaline R, Thompson DG, Dockray GJ:
Expression of cannabinoid CB1 receptors by vagal afferent neurons is
inhibited by cholecystokinin. J Neurosci 2004, 24:2708–2715.
66. DiPatrizio NV, Astarita G, Schwartz G, Li X, Piomelli D: Endocannabinoid
signal in the gut controls dietary fat intake. Proc Natl Acad Sci U S A 2011,
108:12904–12908.
67. Izzo AA, Fezza F, Capasso R, Bisogno T, Pinto L, Iuvone T, Esposito G,
Mascolo N, Di Marzo V, Capasso F: Cannabinoid CB1-receptor mediated
regulation of gastrointestinal motility in mice in a model of intestinal
inflammation. Br J Pharmacol 2001, 134:563–570.
68. Pertwee RG: Cannabinoids and the gastrointestinal tract. Gut 2001,
48:859–867.
69. Cani PD: Crosstalk between the gut microbiota and the endocannabinoid
system: impact on the gut barrier function and the adipose tissue.
Clin Microbiol Infect 2012, 18(Suppl 4):50–53.
70. Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y,
Derrien M, Muccioli GG, Delzenne NM, de Vos WM, Cani PD: Cross-talk
between Akkermansia muciniphila and intestinal epithelium controls
diet-induced obesity. Proc Natl Acad Sci U S A 2013, 110:9066–9071.
Dunn et al. Nutrition & Metabolism 2014, 11:24 Page 12 of 12
http://www.nutritionandmetabolism.com/content/11/1/2471. Garcia TP, Muller S, Carroll RJ, Dunn TN, Thomas AP, Adams SH, Pillai SD,
Walzem RL: Structured variable selection with q-values. Biostatistics 2013,
14:695–707.
72. Naughton SS, Mathai ML, Hryciw DH, McAinch AJ: Fatty Acid modulation
of the endocannabinoid system and the effect on food intake and
metabolism. Int J Endocrinol 2013, 2013:361895.
73. Calder PC, Albers R, Antoine JM, Blum S, Bourdet-Sicard R, Ferns GA, Folkerts
G, Friedmann PS, Frost GS, Guarner F, Løvik M, Macfarlane S, Meyer PD,
M'Rabet L, Serafini M, van Eden W, van Loo J, Vas Dias W, Vidry S,
Winklhofer-Roob BM, Zhao J: Inflammatory disease processes and
interactions with nutrition. Br J Nutr 2009, 101(Suppl 1):S1–S45.
doi:10.1186/1743-7075-11-24
Cite this article as: Dunn et al.: A diet containing a nonfat dry milk
matrix significantly alters systemic oxylipins and the endocannabinoid
2-arachidonoylglycerol (2-AG) in diet-induced obese mice. Nutrition &
Metabolism 2014 11:24.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
